ALLOGENE THERAPEUTICS INC. - COMMON STOCK

Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update

07 Nov 2024 15:02:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

07 Nov 2024 09:00:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting

05 Nov 2024 08:10:30 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in November Investor Conferences

04 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

30 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

29 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference

30 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence

26 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

08 Aug 2024 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update 

07 Aug 2024 15:02:54 By Nasdaq GlobeNewswire

Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update

31 Jul 2024 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)

01 Jul 2024 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse

20 Jun 2024 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit

23 May 2024 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock

13 May 2024 15:47:42 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update

13 May 2024 15:01:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

06 May 2024 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

26 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Q2 Investor Conference Participation

09 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update

14 Mar 2024 15:05:00 By Nasdaq GlobeNewswire